Novartis?s Lucentis Fails to Win Backing for Eye Condition U.K. Review bi13750916 Novartis AG (NOVN) ?s Lucentis eye drug failed to win the backing of the U.K.?s health-cost agency final guidelines on the of diabetic macular edema

Akebia Initiates Phase 1 Study of First-In-Class HPTP? Inhibitor for Diabetic bi13750916 CINCINNATI--(BUSINESS WIRE)--Akebia Therapeutics has initiated Phase 1 clinical trial of AKB-9778 to evaluate safety, tolerability and pharmacokinetics for the of diabetic macular edema and diabetic retinopathy

pSivida Reports Receipt by Alimera Sciences of Complete Response Letter from bi13750916 pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader developing sustained release, drug delivery products for of back-of-the-eye diseases, today reported that licensee Alimera Sciences, Inc. (Alimera) ..

Alimera plunges as FDA asks for new Iluvien trials bi13750916 Alimera Sciences Inc. said Friday that regulators have again refused to approve retinal disease Iluvien, and asked to run two new clinical trials

Regeneron Announces FDA Approval of EYLEA? (aflibercept) Injection for the Tr bi13750916 TARRYTOWN, N.Y., Nov. 18, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA (aflibercept) Injection, known the scientific literature as VEGF Trap-Eye, for the..

Novartis?s Lucentis Fails to Win Backing for Eye Condition U.K. Review bi13750916 Novartis AG (NOVN) ?s Lucentis eye drug failed to win the backing of the U.K.?s health-cost agency final guidelines on the of diabetic macular edema

Akebia Initiates Phase 1 Study of First-In-Class HPTP? Inhibitor for Diabetic bi13750916 CINCINNATI--(BUSINESS WIRE)--Akebia Therapeutics has initiated Phase 1 clinical trial of AKB-9778 to evaluate safety, tolerability and pharmacokinetics for the of diabetic macular edema and diabetic retinopathy

Alimera plunges as FDA asks for new Iluvien trials bi13750916 Alimera Sciences Inc. said Friday that regulators have again refused to approve retinal disease Iluvien, and asked to run two new clinical trials

Regeneron Announces FDA Approval Of EYLEA? (Aflibercept) Injection For The Tr bi13750916 Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA (aflibercept) Injection, known the scientific literature as VEGF Trap-Eye, for the of patients neovascular (wet) Age-related Macular Degeneration (AMD) at a recommended dose of 2 milligrams (mg) every four weeks (monthly) for the first 12 weeks ..

Alimera Sciences Fails to Win FDA Approval for Eye Drug bi13750916 Alimera Sciences Inc. failed to win U.S. backing to market first product, an eye for people diabetes

Santarus and Pharming announce oral presentations of retrospective analyses o bi13750916 LEIDEN, NETHERLANDS-- -Biotech company Pharming Group NV and specialty biopharmaceutical company Santarus,Inc. today announced that retrospective analyses ofintegratedefficacy data and immuno-safety data ..

Horizon Pharma Announces Launch of DUEXIS(R) (Ibuprofen/Famotidine) 800 mg/26 bi13750916 DEERFIELD, IL-- - Horizon Pharma, Inc. today announced that DUEXIS® , a proprietary single-tablet combination of ibuprofen and famotidine , now available to U.S. physicians for the relief of signs and ..

Press Release bi13750916 pSivida Corp. Posted on:11 Nov 11 pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader developing sustained release, drug delivery products for of back-of-the-eye diseases, today reported that licensee Alimera Sciences, Inc. (Alimera) received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) response to the New Drug Application (NDA) for ILUVIEN® ..

Brake Pad Change - Home